Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?

NCT00813514 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Choroidal NeoVascularization
Age-Related Macular Degeneration

Interventions

GENETIC: VEGF genotyping

Sponsor

Medical University of Vienna